Bruker (NASDAQ:BRKR) Price Target Cut to $70.00 by Analysts at TD Cowen

Bruker (NASDAQ:BRKR) had its target price trimmed by TD Cowen from $72.00 to $70.00 in a report issued on Wednesday morning,Benzinga reports. The firm currently has a hold rating on the medical research company’s stock.

Several other analysts have also recently commented on the company. Wells Fargo & Company decreased their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday. Barclays decreased their price target on Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a report on Wednesday. Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. Citigroup decreased their price target on Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday, July 10th. Finally, The Goldman Sachs Group decreased their price target on Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a report on Tuesday, July 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $79.36.

Bruker Stock Performance

Shares of NASDAQ:BRKR opened at $57.73 on Wednesday. The business’s fifty day moving average price is $63.64 and its two-hundred day moving average price is $66.21. Bruker has a fifty-two week low of $54.55 and a fifty-two week high of $94.86. The stock has a market capitalization of $8.74 billion, a price-to-earnings ratio of 27.75, a price-to-earnings-growth ratio of 2.83 and a beta of 1.20. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.75.

Bruker (NASDAQ:BRKR) last announced its earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). The business had revenue of $864.40 million for the quarter, compared to the consensus estimate of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. Bruker’s revenue for the quarter was up 16.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.74 EPS. As a group, analysts predict that Bruker will post 2.39 EPS for the current fiscal year.

Institutional Investors Weigh In On Bruker

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its position in Bruker by 20.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 991 shares of the medical research company’s stock valued at $63,000 after buying an additional 165 shares during the last quarter. Securian Asset Management Inc. raised its position in Bruker by 2.3% in the 2nd quarter. Securian Asset Management Inc. now owns 7,766 shares of the medical research company’s stock valued at $496,000 after buying an additional 175 shares during the last quarter. Covestor Ltd raised its position in Bruker by 139.1% in the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after buying an additional 210 shares during the last quarter. First Horizon Advisors Inc. raised its position in Bruker by 120.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after buying an additional 218 shares during the last quarter. Finally, Ameritas Investment Partners Inc. raised its position in Bruker by 0.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 30,911 shares of the medical research company’s stock valued at $1,972,000 after buying an additional 235 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.